WST files 8-K, furnishes Q2 2025 results press release & deck
On 24 July 2025, West Pharmaceutical Services, Inc. (NYSE: WST) filed a Form 8-K disclosing that it has furnished (not filed) its second-quarter 2025 results under Item 2.02 and Item 7.01.
Rhea-AI Filing Summary
On 24 July 2025, West Pharmaceutical Services, Inc. (NYSE: WST) filed a Form 8-K disclosing that it has furnished (not filed) its second-quarter 2025 results under Item 2.02 and Item 7.01. The company attached two exhibits:
- 99.1 – press release announcing Q2 2025 financial results
- 99.2 – investor presentation used on the accompanying conference call
Positive
- The company timely disclosed its Q2 2025 results materials, maintaining regulatory compliance and transparency.
Negative
- The filing provides no quantitative results or guidance, forcing investors to seek separate exhibits for critical data.
Insights
TL;DR: Notice of Q2 results only; no numbers—impact neutral until exhibits reviewed.
The 8-K meets disclosure requirements but offers no financial detail. Investors must examine Exhibits 99.1 and 99.2 to gauge revenue, margin trends, or updated guidance. Because the core data are outside the filing, the market impact is deferred until those materials are digested. From a valuation standpoint this document alone is information-light, neither positive nor negative.
TL;DR: Properly furnished under Items 2.02/7.01; limits liability.
The company correctly classified the release as furnished, shielding it from Section 18 liability. No emerging growth company status is asserted. Procedurally sound; no red flags. Impact largely compliance-related rather than financial.
8-K Event Classification
3 items: 2.02, 7.01, 9.01
3 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
FAQ
When did West Pharmaceutical Services (WST) release its Q2 2025 results?
The company announced its second-quarter 2025 results on July 24, 2025.
Where can investors find West Pharmaceutical's Q2 2025 press release?
The press release is attached as Exhibit 99.1 to the Form 8-K and is posted under the Investors section of westpharma.com.
What exhibits are included in the July 24, 2025 Form 8-K?
Exhibit 99.1 (press release), Exhibit 99.2 (investor presentation), and Exhibit 104 (Inline XBRL cover page).
Is the information in this 8-K considered filed or furnished?
It is furnished under Items 2.02 and 7.01, so it is not deemed "filed" for Exchange Act Section 18 purposes.
Who signed West Pharmaceutical Services' July 24, 2025 Form 8-K?
The report was signed by Bernard J. Birkett, Senior Vice President & Chief Financial Officer.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) – July 24, 2025
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
(Address of principal executive offices) | (Zip Code) | |||||||||||||
Registrant’s telephone number, including area code: 610 -594-2900
Not Applicable | ||
(Former name or address, if changed since last report.) | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
1
Item 2.02 Results of Operations and Financial Condition.
On July 24, 2025, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing its second-quarter 2025 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 7.01 Regulation FD Disclosure.
The information set forth in “Item 2.02 Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference.
A copy of the Company’s presentation materials used during the call will be available through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference.
The information in this report (including the exhibits attached hereto) is being furnished pursuant to Item 2.02 and Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) | Exhibit No. | Description | ||||||
99.1 | West Pharmaceutical Services, Inc. Press Release, dated July 24, 2025. | |||||||
99.2 | West Pharmaceutical Services, Inc. Presentation, dated July 24, 2025. | |||||||
104 | The cover page from the Company’s Current Report on Form 8-K, dated July 24, 2025, formatted in Inline XBRL. | |||||||
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
WEST PHARMACEUTICAL SERVICES, INC. | |||||
/s/ Bernard J. Birkett | |||||
| Bernard J. Birkett | |||||
| Senior Vice President, Chief Financial Officer | |||||
| July 24, 2025 | |||||
3
EXHIBIT INDEX
Exhibit No. | Description | |||||||
99.1 | West Pharmaceutical Services, Inc. Press Release, dated July 24, 2025. | |||||||
99.2 | West Pharmaceutical Services, Inc. Presentation, dated July 24, 2025. | |||||||
104 | The cover page from the Company’s Current Report on Form 8-K, dated July 24, 2025, formatted in Inline XBRL. | |||||||
4